Financiado en parte por Bio-Tech Pharmacal
Breast cancer risk markedly lower with serum 25-hydroxyvitamin D concentrations ≥60 vs <20 ng/ml (150 vs 50 nmol/L): Pooled analysis of two randomized trials and a prospective cohort
McDonnell SL, Baggerly CA, French CB, Baggerly LL, Garland CF, Gorham ED, Hollis BW, Trump DL, Lappe JM
PloS one · 99 citas
Etiquetas de revisión
Financiado por la industriaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Estudio de cohortes (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiado por la industria
- Universidad u hospital
- Creighton University
- Empresa
- Bio-Tech Pharmacal
- Organización sin fines de lucro
- Vitamin D Society
- Universidad u hospital
- University of Texas MD Anderson Cancer Center
- Gobierno
- National Cancer Institute
Según 5 financiadores declarados y la declaración de financiación del texto completo.
Publicación
- Publicado
- 2018-06-15 · PLoS One · vol. 13 · número 6 · pág. e0199265
- Editorial
- Public Library of Science
- Citado
- 118 citas · más que el 99% de estudios similares · 9.9× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 49 trabajos
- Acceso
- Acceso abierto (revista) · PUBLIC-DOMAIN
- Áreas de investigación
- Vitamin D Research Studies · Thyroid Disorders and Treatments · Estrogen and related hormone effects
- Palabras clave
- Breast cancer, Medicine, Prospective cohort study, Internal medicine, Proportional hazards model, Incidence (geometry), Cancer, Cohort, Cohort study, Gastroenterology, Gynecology
- MeSH
- humans, breast neoplasms, vitamin d, proportional hazards models, risk factors, prospective studies, aged, aged, 80 and over, middle aged, female, randomized controlled trials as topic
9 autores
- Sharon L. McDonnell🇺🇸 · autor de correspondenciaGrassrootsHealth
- Carole A. Baggerly🇺🇸GrassrootsHealth
- Christine French🇺🇸GrassrootsHealth
- Leo L. Baggerly🇺🇸GrassrootsHealth
- Cedric F. Garland🇺🇸University of California San Diego
- Edward Doerr Gorham🇺🇸University of California San Diego
- Bruce W. Hollis🇺🇸Medical University of South Carolina
- Donald L. Trump
- Joan M. Lappe🇺🇸Creighton University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
While numerous epidemiologic studies have found an association between higher serum 25-hydroxyvitamin D [25(OH)D] concentrations and lower breast cancer risk, few have assessed this association for concentrations >40 ng/ml.
Objective
To investigate the relationship between 25(OH)D concentration and breast cancer risk across a broad range of 25(OH)D concentrations among women aged 55 years and older.
Methods
Analyses used pooled data from two randomized clinical trials (N = 1129, N = 2196) and a prospective cohort (N = 1713) to examine a broad range of 25(OH)D concentrations. The outcome was diagnosis of breast cancer during the observation periods (median: 4.0 years). Three analyses were conducted: 1) Incidence rates were compared according to 25(OH)D concentration from <20 to ≥60 ng/ml (<50 to ≥150 nmol/L), 2) Kaplan-Meier plots were developed and 3) multivariate Cox regression was used to examine the association between 25(OH)D and breast cancer risk using multiple 25(OH)D measurements.
Results
Within the pooled cohort (N = 5038), 77 women were diagnosed with breast cancer (age-adjusted incidence: 512 cases per 100,000 person-years). Results were similar for the three analyses. First, comparing incidence rates, there was an 82% lower incidence rate of breast cancer for women with 25(OH)D concentrations ≥60 vs <20 ng/ml (Rate Ratio = 0.18, P = 0.006). Second, Kaplan-Meier curves for concentrations of <20, 20-39, 40-59 and ≥60 ng/ml were significantly different (P = 0.02), with the highest proportion breast cancer-free in the ≥60 ng/ml group (99.3%) and the lowest proportion breast cancer-free in the <20 ng/ml group (96.8%). The proportion with breast cancer was 78% lower for ≥60 vs <20 ng/ml (P = 0.02). Third, multivariate Cox regression revealed that women with 25(OH)D concentrations ≥60 ng/ml had an 80% lower risk of breast cancer than women with concentrations <20 ng/ml (HR = 0.20, P = 0.03), adjusting for age, BMI, smoking status, calcium supplement intake, and study of origin.
Conclusions
Higher 25(OH)D concentrations were associated with a dose-response decrease in breast cancer risk with concentrations ≥60 ng/ml being most protective.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC0).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.